Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development (Q34900298)

5 August 2017

1 reference

title

Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development (English)

1 reference

5 August 2017

1 reference

ChEBI release 2020-05-28

1 reference

1 reference

3

Jeffrey I Weitz

1 reference

5 August 2017

2

Daniel J Quinlan

1 reference

5 August 2017

Bengt I Eriksson

1

1 reference

5 August 2017

publication date

1 January 2009

1 reference

Clinical Pharmacokinetics

5 August 2017

published in

1 reference

5 August 2017

volume

48

1 reference

5 August 2017

issue

1

1 reference

5 August 2017

page(s)

1-22

1 reference

Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor

5 August 2017

cites work

1 reference

12 December 2020

Characterization of in Vitro Biotransformation of New, Orally Active, Direct Thrombin Inhibitor Ximelagatran, an Amidoxime and Ester Prodrug

1 reference

12 December 2020

Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery.

1 reference

12 December 2020

Subcutaneous Fondaparinux versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary Embolism

1 reference

12 December 2020

In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban

1 reference

12 December 2020

The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement.

1 reference

12 December 2020

Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study

1 reference

12 December 2020

Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin

1 reference

12 December 2020

Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis

1 reference

12 December 2020

The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects

1 reference

12 December 2020

Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement

1 reference

12 December 2020

Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor

1 reference

12 December 2020

BIBR-1048 Boehringer Ingelheim

1 reference

12 December 2020

Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation

1 reference

12 December 2020

The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans

1 reference

12 December 2020

Prothrombin protects factor Xa in the prothrombinase complex from inhibition by the heparin-antithrombin complex

1 reference

12 December 2020

Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber

1 reference

12 December 2020

Protease inhibitors in the clinic.

1 reference

12 December 2020

Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a

1 reference

12 December 2020

Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor xa inhibitor--in healthy subjects

1 reference

12 December 2020

Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data

1 reference

12 December 2020

Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects

1 reference

12 December 2020

Pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--in rats and dogs

1 reference

12 December 2020

Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor

1 reference

12 December 2020

Comparison of fondaparinux and enoxaparin in acute coronary syndromes

1 reference

12 December 2020

New oral anticoagulants in atrial fibrillation

1 reference

12 December 2020

DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles

1 reference

12 December 2020

The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review

1 reference

12 December 2020

Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits

1 reference

12 December 2020

Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.

1 reference

12 December 2020

Three different patterns of calibrated automated thrombogram obtained with six different anticoagulants

1 reference

12 December 2020

Discovery of piperazinylimidazo[1,2-a]pyridines as novel S4 binding elements for orally active factor Xa inhibitors

1 reference

12 December 2020

A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.

1 reference

12 December 2020

Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans

1 reference

12 December 2020

The discovery of (2R,4R)-N-(4-chlorophenyl)-N- (2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl)-4-methoxypyrrolidine-1,2-dicarboxamide (PD 0348292), an orally efficacious factor Xa inhibitor

1 reference

12 December 2020

Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) Study

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment

1 reference

12 December 2020

Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.

1 reference

12 December 2020

Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis

1 reference

12 December 2020

Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor

1 reference

12 December 2020

Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--has no clinically relevant interaction with naproxen

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects

1 reference

12 December 2020

Building individualized medicine: prevention of adverse reactions to warfarin therapy

1 reference

12 December 2020

Characterization of a tubular flow chamber for studying platelet interaction with biologic and prosthetic materials: deposition of indium 111-labeled platelets on collagen, subendothelium, and expanded polytetrafluoroethylene.

1 reference

12 December 2020

Anti-Xa and anti-IIa drugs alter international normalized ratio measurements: potential problems in the monitoring of oral anticoagulants

1 reference

12 December 2020

New heparin complexes active by intestinal absorption: I-multiple ion pairs with basic organic compounds

1 reference

12 December 2020

A review of the effects of the oral direct thrombin inhibitor ximelagatran on coagulation assays.

1 reference

12 December 2020

In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor

1 reference

12 December 2020

Iliac venous stenting: antithrombotic efficacy of PD0348292, an oral direct Factor Xa inhibitor, compared with antiplatelet agents in pigs.

1 reference

12 December 2020

Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats

1 reference

12 December 2020

Direct thrombin inhibitors

1 reference

12 December 2020

Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty

1 reference

12 December 2020

A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement

1 reference

12 December 2020

A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery

1 reference

12 December 2020

Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity

1 reference

12 December 2020

In vitro intestinal permeability of factor Xa inhibitors: influence of chemical structure on passive transport and susceptibility to efflux

1 reference

12 December 2020

Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis

1 reference

12 December 2020

In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate

1 reference

12 December 2020

Emerging anticoagulants for the treatment of venous thromboembolism

1 reference

12 December 2020

Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate

1 reference

12 December 2020

Rivaroxaban--an oral, direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopenia

1 reference

12 December 2020

Structure-based design of novel potent nonpeptide thrombin inhibitors

1 reference

12 December 2020

New anticoagulants for treatment of venous thromboembolism

1 reference

12 December 2020

Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood [...]

1 reference

12 December 2020

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

1 reference

12 December 2020

Synthetic inhibitors of thrombin and factor Xa: from bench to bedside

1 reference

12 December 2020

Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery.

1 reference

12 December 2020

Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects.

1 reference

12 December 2020

Discovery of imidazo[1,5-c]imidazol-3-ones: weakly basic, orally active factor Xa inhibitors

1 reference

12 December 2020

Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects

1 reference

12 December 2020

DU-176b, an oral, direct Factor Xa antagonist

1 reference

12 December 2020

Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies

1 reference

12 December 2020

Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I.

1 reference

12 December 2020

Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery

1 reference

12 December 2020

Small molecule coagulation cascade inhibitors in the clinic

1 reference

12 December 2020

Comparison of PD0348292, a selective factor Xa inhibitor, to antiplatelet agents for the inhibition of arterial thrombosis

1 reference

12 December 2020

Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases

1 reference

12 December 2020

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.

1 reference

12 December 2020

Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects

1 reference

12 December 2020

Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial

1 reference

12 December 2020

Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement

1 reference

12 December 2020

A new oral anticoagulant: the 50-year challenge

1 reference

12 December 2020

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty

1 reference

12 December 2020

10.2165/0003088-200948010-00001

Identifiers

DOI

1 reference

Dimensions Publication ID

5 August 2017

1046841512

0 references

1 reference